Sponsor Deadline
Posted: 4/18/2022

Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)

The purpose of this FOA is to establish Technology and Analytic Cores (TACs) and a Research Management Unit (RMU) for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. The TACs include the Technology Cores and the specialized Tissue Repository and Systems Biology Cores. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. TACs will work together to test, optimize and apply state-of-the-art and next-generation high-dimensional, high-resolution technologies to interrogate and analyze human biopsy tissue and biosamples from patients with rheumatoid arthritis, lupus, psoriatic spectrum disease and Sjögren’s syndrome. The RMU will provide centralized management and operational support to the network including clinical monitoring for the entire AMP AIM program. All Cores and the RMU will work collaboratively with the Disease Teams (RFA-AR-21-015) to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue involvement in relevant patient populations.


  • Letter of Intent: June 15, 2021
  • Application: July 15, 2021

RFA-AR-21-016 Expiration Date July 16, 2021